RAPGEF5 and breast carcinoma: The PI3K‐AKT–mTOR pathway is activated via ERα and growth factor receptor (GFR) family members, which are considered to be a turntable for bidirectional crosstalk between the ER and HER2 pathways, making it a viable alternative strategy in breast cancer management.42